1. Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases
- Author
-
V Barbetti, R Rembado, M. Foglia, G. P. Vigliercio, F Corongiu, A. Calabrese, and G. C. Torre
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Adolescent ,Genital Neoplasms, Female ,Trypsin inhibitor ,Microgram ,Clinical Biochemistry ,Gastroenterology ,Sensitivity and Specificity ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Stage (cooking) ,Tumor-Associated Trypsin Inhibitor ,Retrospective Studies ,business.industry ,Smoking ,Cancer ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,Trypsin Inhibitor, Kazal Pancreatic ,Genital neoplasm ,Female ,Ovarian Mucinous Tumor ,business ,Genital Diseases, Female - Abstract
The behavior of tumor-associated trypsin inhibitor (TATI) as a marker for gynecological cancer was studied in a control population and in patients with different benign and malignant diseases. When a cut-off level of 21.4 micrograms/l was used the specificity was 100% in patients with benign diseases. The sensitivity in patients with malignant tumors was low for cervical and corpus cancer, 13% and 14%, respectively, whereas it was 33% in all the ovarian malignant tumors, reaching 60% in the mucinous type. There was a clear correlation between TATI level and stage.
- Published
- 1991